AbbVie’s Risankizumab (SKYRIZI®) shows positive phase III results in Patients with Crohn’s Disease
AbbVie announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg ...
Read more
Tag: risankizumab
